Read our Recent Headlines


Aug 16, 2019 by Dave Sobek

August 16th Biotech Update

So far the week is ending on a positive note but it is early but not surprising that we see some sort of bounce in the market. I sort of.

Share 0 Comments Read more
Aug 15, 2019 by Dave Sobek

August 15 Biotech Update

While the macro has been major the past couple of days, the sector specific news has been pretty sparse. I was hoping something interesting would happen to write about but.

Aug 14, 2019 by Jason Chew

Coverage Continuation – ZYME

Aug 14, 2019 by Jason Chew Zymeworks is perhaps one of my favorite stocks. The small/mid cap Canadian biotech has expertise in bispecific antibody technology. Bispecifics are an exploding field,.

Aug 13, 2019 by Dave Sobek

August 13 Biotech News

We are back into the old pattern. Good biotech news that moves the individual stock but has limited read through. We have had a couple of these days where the.

Aug 12, 2019 by Jason Chew

Coverage Continuation: SAGE

It has been a long time since my last article, but with the forum down, there is a lot to catch up on. My coverage will focus on the eight.

Aug 12, 2019 by Dave Sobek

August 12th Biotech Update

Another week with another set of macro concerns. I was waiting to see if there would be any interesting biotech news but I guess not. There was some late last.

Aug 09, 2019 by Dave Sobek

August 9th Biotech Update

It has been 24 hours of surprises culminating in my daughters school bus not showing up this morning but that is the least of the surprises. Interestingly, the broader sector.

More From All Reports

Introduction


[videojs width="640" preload="auto" ogg="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640ogg.ogg" webm="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640webm.webm" mp4="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640mp4.mp4"]

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More